ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) Alone and TACE in Combination With Other Treatment Modalities

J. Balogh, A. Islam, A. Saharia, H. Monsour, S. Gordon Burroughs, M. Weiner, A. Gaber, R. Ghobrial.

General Surgery, Houston Methodist Hospital, Houston, TX.

Meeting: 2015 American Transplant Congress

Abstract number: D189

Keywords: Hepatocellular carcinoma, Liver transplantation, Recurrence, Survival

Session Information

Session Name: Poster Session D: Liver Transplantation for Hepatocellular Carcinoma

Session Type: Poster Session

Date: Tuesday, May 5, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

AIM:

Treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) can help downstage tumors prior to orthotopic liver transplantation (OLT); however, there is a risk of tumor recurrence. The aim of this study was to examine the incidence of HCC recurrence after TACE versus after TACE and an additional treatment modality in patients who underwent OLT.

METHODS:

This is a single center retrospective review. From 4/2007 to 12/2011, 44/121 patients (36%) who underwent TACE ultimately proceeded to OLT. These 44 were treated prior to transplant in 1 of 5 ways: 1) TACE alone, 2) TACE + radiofrequency ablation (RFA), 3) TACE + chemotherapy, 4) TACE + RFA + chemotherapy, or 5) TACE + Yttrium sphere (Y90) therapy. Tumor recurrence was measured by increasing AFP post-transplant and/or positive surveillance MRI and confirmation with histology on biopsy.

RESULTS:

In the 44 patients who received TACE +/- another modality and proceeded to OLT, the average number of clinical tumor number was 2, , clinical maximum tumor size 2.96 cm and clinical total tumor size of 4.57 cm. Average explant tumors was 2.46 with total tumor size of 5.5cm; average percent necrosis was 63%. Seven (16%) of these patients had HCC recurrence that occurred at a median of 542 days post-transplant. Average number of explant tumors in this subset was 1.43 with a total tumor size of 6.32 cm; average percent necrosis was 51%. Among these 7 patients, 5 (71%) had been treated with TACE alone, and 2 (29%) were treated with TACE + chemotherapy. There were no recurrences in the RFA or Y90 groups. The average number of TACE procedures per patient in those with recurrences was 2.14. The disease-free survival rate at 1-, 3-, and 5-years post-transplant was 71%, 57%, and 57%, respectively.

CONCLUSIONS:

In our single center experience, there was a 15% HCC recurrence rate after treatment with TACE. In these patients, more aggressive treatment with TACE in addition to another modality (RFA or Y90) should be considered prior to transplant.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Balogh J, Islam A, Saharia A, Monsour H, Burroughs SGordon, Weiner M, Gaber A, Ghobrial R. Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) Alone and TACE in Combination With Other Treatment Modalities [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/recurrence-of-hepatocellular-carcinoma-after-transarterial-chemoembolization-tace-alone-and-tace-in-combination-with-other-treatment-modalities/. Accessed May 14, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences